![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Departments of Investigative and Cardiac Biology and Vascular Biology, Cardiovascular and Urogenital Center of Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, Pennsylvania
Numerous mediators, believed to play a role in endothelial dysfunction (e.g., neurohormones, cytokines, hypoxia, and stretch), have been shown to activate p38 mitogen-activated protein kinase (MAPK) in a variety of cell types. The purpose of the present study was to examine the regulation of p38 MAPK in endothelium and its role in endothelial dysfunction and salt sensitivity. In cultured human umbilical vein endothelial cells (HUVECs), tumor necrosis factor-
and lipopolysaccharide increased phosphorylation of p38 MAPK (P-p38 MAPK) and increased ICAM-1 expression. Preincubation with highly selective p38 MAPK inhibitors, 1-(1,3-dihydroxyprop-2-yl)-4-(4-fluorophenyl)-5-[2-phenoxypyrimidin-4-yl] imidazole (SB-239063AN) or SB-239063, dose dependently reduced intercellular adhesion molecule-1 expression in HUVECs. In spontaneously hypertensive-stroke prone rats (SHR-SP), P-p38 MAPK was localized by immunohistochemistry to the aortic endothelium and adventitia but was undetectable in aortae from normotensive rats. Introduction of a salt/fat diet (SFD) to the SHR-SP strain induced endothelial dysfunction (ex vivo vascular reactivity analysis), albuminuria, and an increase in blood pressure within 4 weeks. Chronic dietary dosing (approx. 100 mg/kg/day) with SB-239063AN inhibited the SFD diet-induced hypertension. In addition, delayed treatment also significantly improved survival and restored nitric oxide-mediated endothelium-dependent relaxation in SFD-SHR-SPs with established endothelial dysfunction. These results suggest an important role for p38 MAPK in endothelial inflammation and dysfunction as well as providing the first evidence for p38 MAPK-dependent hypertension.
Address correspondence to: Dr. Robert N. Willette, Department of Investigative and Cardiac Biology, UW2510, GlaxoSmithKline, 709 Swedeland Rd., P.O. Box 1539, King of Prussia, PA 19406. E-mail: Robert_n_willette{at}gsk.com
This article has been cited by other articles:
![]() |
Y. Li, X. Zhang, B. Zhu, and Z. Xue Desflurane Preconditioning Inhibits Endothelial Nuclear Factor-{kappa}-B Activation by Targeting the Proximal End of Tumor Necrosis Factor-{alpha} Signaling Anesth. Analg., May 1, 2008; 106(5): 1473 - 1479. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Morris, A. R. Olzinski, R. E. Bernard, K. Aravindhan, R. C. Mirabile, R. Boyce, R. N. Willette, and B. M. Jucker p38 MAPK Inhibition Reduces Aortic Ultrasmall Superparamagnetic Iron Oxide Uptake in a Mouse Model of Atherosclerosis: MRI Assessment Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 265 - 271. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Li, E. J. Barrett, M. O. Barrett, W. Cao, and Z. Liu Tumor Necrosis Factor-{alpha} Induces Insulin Resistance in Endothelial Cells via a p38 Mitogen-Activated Protein Kinase-Dependent Pathway Endocrinology, July 1, 2007; 148(7): 3356 - 3363. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-Y. Liu, Q. F. Collins, Y. Xiong, F. Moukdar, E. G. Lupo Jr., Z. Liu, and W. Cao Prolonged Treatment of Primary Hepatocytes with Oleate Induces Insulin Resistance through p38 Mitogen-activated Protein Kinase J. Biol. Chem., May 11, 2007; 282(19): 14205 - 14212. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Chai and Z. Liu p38 Mitogen-Activated Protein Kinase Mediates Palmitate-Induced Apoptosis But Not Inhibitor of Nuclear Factor-{kappa}B Degradation in Human Coronary Artery Endothelial Cells Endocrinology, April 1, 2007; 148(4): 1622 - 1628. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Doe, R. Bentley, D. J. Behm, R. Lafferty, R. Stavenger, D. Jung, M. Bamford, T. Panchal, E. Grygielko, L. L. Wright, et al. Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 89 - 98. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nozawa, K.-i. Sugimoto, M. Ohmori, H. Ando, and A. Fujimura Dosing Time-Dependent Effect of Temocapril on the Mortality of Stroke-Prone Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 176 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Cao, Q. F. Collins, T. C. Becker, J. Robidoux, E. G. Lupo Jr., Y. Xiong, K. W. Daniel, L. Floering, and S. Collins p38 Mitogen-activated Protein Kinase Plays a Stimulatory Role in Hepatic Gluconeogenesis J. Biol. Chem., December 30, 2005; 280(52): 42731 - 42737. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li and E. P. Nord CD40/CD154 ligation induces mononuclear cell adhesion to human renal proximal tubule cells via increased ICAM-1 expression Am J Physiol Renal Physiol, July 1, 2005; 289(1): F145 - F153. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. McMullen, P. W. Bryant, C. C. Glembotski, P. A. Vincent, and K. M. Pumiglia Activation of p38 Has Opposing Effects on the Proliferation and Migration of Endothelial Cells J. Biol. Chem., June 3, 2005; 280(22): 20995 - 21003. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Olzinski, T. A. McCafferty, S. Q. Zhao, D. J. Behm, M. E. Eybye, K. Maniscalco, R. Bentley, K. S. Frazier, C. M. Milliner, R. C. Mirabile, et al. Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection Cardiovasc Res, April 1, 2005; 66(1): 170 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Widder, T. Behr, D. Fraccarollo, K. Hu, P. Galuppo, P. Tas, C. E Angermann, G. Ertl, and J. Bauersachs Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent Cardiovasc Res, July 1, 2004; 63(1): 161 - 167. [Abstract] [Full Text] [PDF] |
||||